Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 7, 2006, Pages 1892-1897

  Büttelmann, Bernd ^a   Peters, Jens Uwe ^a   Ceccarelli, Simona ^a   Kolczewski, Sabine ^a   Vieira, Eric ^a   Prinssen, Eric P ^a   Spooren, Will ^a   Schuler, Franz ^a   Huwyler, Jörg ^a   Porter, Richard H P ^a   Jaeschke, Georg ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anxiolysis; Anxiolytic; Metabotropic glutamate receptor; mGluR5

Indexed keywords

GLUTAMATE RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; NONHUMAN; RAT; RECEPTOR BINDING;

ADMINISTRATION, ORAL; EXCITATORY AMINO ACID ANTAGONISTS; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE;

ANIMALIA;

EID: 33144489592     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.12.088     Document Type: Article

References (31)

1. R. Dingledine, K. Borges, D. Bowie, and S.F. Traynelis Pharmacol. Rev. 51 1999 7
2. J. Pin, C. De Colle, A. Bessis, and F. Acher Eur. J. Pharmacol. 375 1999 277
3. L.J. O'Hara, P.O. Sheppard, H. Thogersen, D. Venezia, B.A. Haldema, V. MacGrane, K.M. Houamed, C. Thomsen, E.R. Gilbert, and E.R. Mulvihill Neuron 11 1993 41
4. J.P. Conn, and J.P. Pin Annu. Rev. Pharmacol. Toxicol. 37 1997 205
5. T. Knöpfel, R. Kuhn, and H. Allgeier J. Med. Chem. 38 1995 1417
6. W.P.J.M. Spooren, F. Gasparini, T.E. Salt, and R. Kuhn Trends Pharmacol. Sci. 22 2001 331
7. R. Shigemoto, S. Nomura, H. Ohishi, H. Sugihara, S. Nakanishi, and N. Mizuno Neurosci. Lett. 163 1993 53
8. C. Romano, M.A. Sesma, C.T. McDonald, K. O'Malley, A.N. VandenPol, and J.W. Olney J. Compar. Neurol. 355 1995 455
9. T.M. Ballard, M.L. Woolley, E. Prinssen, J. Huwyler, R. Porter, and W. Spooren Psychopharmacology 179 2005 218
10. R.H.P. Porter, G. Jaeschke, W. Spooren, T. Ballard, B. Buettelmann, S. Kolczewski, J.-U. Peters, E. Prinssen, J. Wichmann, E. Vieira, A. Muehlemann, S. Gatti, V. Mutel, and P. Malherbe J. Pharmacol. Exp. Ther. 315 2005 711
11. J.H. Woods, J.L. Katz, and G. Winger Pharmacol. Rev. 44 1992 151
12. M. Vaswani, F.K. Linda, and S. Ramesh Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 85
13. C.J. Swanson, M. Bures, M.P. Johnson, A.-M. Linden, J.A. Monn, and D.D. Schoepp Nature Rev. Drug. Discovery 42 2005 131
14. W. Spooren, and F. Gasparini Drug News Perspectives 17 2004 251
15. M.J. Bradbury, U. Campbell, D. Giracello, D. Chapman, C. King, L. Tehrani, N.D.P. Cosford, J. Anderson, M.A. Varney, and A.M. Strack J. Pharmacol. Exp. Ther. 313 2005 395
16. N. Breysse, C. Baunez, W. Spooren, F. Gasparini, and M. Amalric J. Neurosci. 22 2002 5669
17. C.Z. Zhu, S.G. Wilson, J.P. Mikusa, C.T. Wismer, D.M. Gauvin, J.L. Lynch III, C.L. Wade, M.W. Decker, and P. Honore Eur. J. Pharmacol. 506 2004 107
18. V. Mutel Exp. Opin. Ther. Pat. 12 2002 1845
19. C. Chiamulera, M.P. Epping-Jordan, A. Zocchi, C. Marcon, C. Cottiny, S. Tacconi, M. Corsi, F. Orzi, and F. Conquet Nat. Neurosci. 4 2001 873
20. M.A. Varney, N.D. Cosford, C. Jachec, S.P. Rao, A. Sacaan, F.F. Lin, L. Bleicher, E.M. Santori, P.J. Flor, H. Allgeier, F. Gasparini, and R. Kuhn J. Pharmacol. Exp. Ther. 290 1999 170
21. F. Gasparini, K. Lingenhohl, N. Stoehr, P.J. Flor, M. Heinrich, I. Vranesic, M. Biollaz, H. Allgeier, R. Heckendorn, S. Urwyler, M.A. Varney, E.C. Johnson, S.D. Hess, S.P. Rao, A.I. Sacaan, E.M. Santori, G. Velicelebi, and R. Kuhn Neuropharmacology 38 1999 1493
22. N.D.P. Cosford, L. Tehrani, J. Roppe, E. Schweiger, N.D. Smith, J. Anderson, L. Bristow, J. Brodkin, X. Jiang, I. McDonald, S. Rao, and M. Washburn J. Med. Chem. 46 2003 402
23. Measurements were performed according to: P. Malherbe, N. Kratochwil, M.-T. Zenner, J. Piussi, C. Diener, C. Kratzeisen, C. Fischer, and R.H.P. Porter Mol. Pharmacol. 64 2003 823
24. R.C.B. Gonzalez, J. Huwyler, F. Boess, I. Walter, and B. Bittner Biopharm. Drug. Dispos. 25 2004 37
25. Measurements were performed according to an in-house developed method to assess solubility from a 10 mM DMSO stock solution. This method is similar to the classical thermodynamic shake-flask solubility with the only difference that DMSO is removed in the beginning by an additional lyophilization step. Therefore, this assay is called LYophilisated Solubility Assay (LYSA).
26. D. Alagille, R.M. Baldwin, B.L. Roth, J.T. Wroblewski, E. Grajkowska, and G.D. Tamagnan Bioorg. Med. Chem. Lett. 15 2005 945
27. D. Alagille, R.M. Baldwin, B.L. Roth, J.T. Wroblewski, E. Grajkowska, and G.D. Tamagnan Bioorg. Med. Chem. 13 2005 197
28. J.R. Vogel, B. Beer, and D.E. Clody Psychopharmacologia 21 1971 1
29. F. Wessely, H. Eibl, and G. Friedrich Monatsh. Chem. 83 1952 24
30. R. Adams, and W. Reifschneider J. Am. Chem. Soc. 79 1957 2236
31. +]. Compounds 24-26 are prepared similarly.